SHANGHAI, March 13,
2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi
XDC", or the "Company", stock code: 2268.HK), a leading global
CRDMO (Contract Research, Development, and Manufacturing
Organization) specializing in antibody-drug conjugates (ADCs) and
other bioconjugates, has been honored with four prestigious awards
at the Asia-Pacific Biopharma Excellence Awards 2025.
The Asia-Pacific Biopharma Excellence Awards honor
companies annually that have exhibited outstanding performance and
achievement in the biopharmaceutical sector. These accolades
underscore WuXi XDC's leadership, innovation, and fully integrated
CRDMO platform, empowering global clients from early discovery to
commercial manufacturing.
- Industry-leading development and manufacturing
capabilities (Best ADC CDMO in Asia & China): WuXi XDC's state-of-the-art facilities
and global dual-sourcing strategy enable seamless CMC development
and GMP manufacturing, accelerating the timeline while ensuring a
high success rate and regulatory excellence.
- Innovation in Discovery & Development (Best ADC CRO
in Asia): WuXi XDC's proprietary
conjugation and payload-linker technologies, along with the
incorporation of external technologies through partnerships, drive
ADC and XDC discovery, optimization, and IND-enabling studies,
expediting clients' clinical advancement.
- Pioneering ADC Technology (Best ADC Platform
Technology): Through next-generation payload-linker innovations and
site-specific conjugation technologies, from internal development
and external partnership, WuXi XDC provides clients with
diversified technology suites to advance ADC and XDC
developments.
Dr. Jimmy Li, CEO of WuXi XDC,
commented: "We are honored to receive these prestigious awards,
which not only reaffirm our team's relentless pursuit of excellence
and innovation in the ADC field but also underscore our dedication
to delivering world-class services that empower our clients to
bring novel therapies to patients worldwide. They are a testament
to the hard work and dedication of every WuXi XDC employee – their
relentless efforts that have made this milestone possible. It also
belongs to our valued partners, whose trust and collaboration have
driven our collective success. Looking ahead, WuXi XDC will
continue to support our clients and advance the innovation and
progress of the global bioconjugate industry."
These awards follow WuXi XDC's recent recognition at the 2024
World ADC Awards, where the company was named Best CDMO
Winner for the second consecutive year, further solidifying
its leadership position in the global ADC industry. As the ADC
market continues to experience sustainable growth, WuXi XDC
relentlessly committed to advancing its technological capabilities
and expanding its service offerings to meet clients' evolving
needs.
About WuXi XDC
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) is
a leading global CRDMO focused on antibody drug conjugates (ADC)
and the broader bioconjugate market. It provides end-to-end
contract research, development and manufacturing services for
bioconjugates, including ADCs. Its services cover antibody
intermediates and other biologics intermediates, chemical payloads
and linkers, as well as bioconjugate drug substances and drug
products. For more information about WuXi XDC, please
visit: www.wuxixdc.com
WuXi XDC Contacts
Investor: wuxixdc.ir@wuxibiologics.com
Media: wuxixdc_pr@wuxibiologics.com
BD: wuxixdc_info@wuxibiologics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/wuxi-xdc-wins-multiple-awards-at-asia-pacific-biopharma-excellence-awards-2025-302400791.html
SOURCE WuXi XDC
